Stocks · News reference

Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est

Jul 30, 2026, 11:01 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 1:57 PMBenzinga Newsdesk
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
Read original at benzinga
PHAT
BenzingaJul 31, 2026, 2:12 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Read original at benzinga
PHAT
BenzingaJul 31, 2026, 10:07 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Read original at benzinga
PHAT
BenzingaJul 30, 2026, 7:25 PMBenzinga Newsdesk
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Read original at benzinga
PHAT